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Abstract
Background: The role of Prostate Specific Antigen (PSA) testing in the early detection of prostate
cancer is controversial. Current UK policy stipulates that any man who wishes to have a PSA test
should have access to the test, provided he has been given full information about the benefits and
limitations of testing. This study aimed to determine UK GPs' current reported practice regarding
PSA testing, and their views towards informed decision-making and PSA testing.
Method:  Online questionnaire survey, with a sample of 421 GPs randomly selected from a
database of GPs across the UK.
Results: 95% (400/421) of GPs responded. 76% of GPs reported having performed a PSA test for
an asymptomatic man at least once in the previous three months, with 13% reported having tested
more than five men in this period. A majority of GPs reported they would do a PSA test for men
presenting with a family history and requesting a test, for asymptomatic men requesting a test and
also for men presenting with lower urinary tract symptoms. Reported testing rates were highest
for men with a family history. Amongst men with lower urinary tract symptoms and men with no
symptoms, reported testing rates were significantly higher for older than younger men.
The majority of GPs expressed support for the current policy (67%), and favoured both the general
practitioner and the man being involved in the decision making process (83%). 90% of GPs indicated
that they would discuss the benefits and limitation of testing with the man, with most (61%)
preferring to ask the man to make a further appointment if he decides to be tested.
Conclusion: This study indicates that PSA testing in asymptomatic men is a regular occurrence in
the UK, and that there is general support from GPs for the current policy of making PSA tests
available to 'informed' men who are concerned about prostate cancer. While most GPs indicated
they would discuss the benefits and limitations prior to PSA testing, and most GPs favoured a
shared approach to decision making, it is not known to what extent men are actually being
informed. Research is needed to evaluate the most effective approach to assisting men in making
an informed decision about whether or not to have a PSA test.
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Background
The increasing incidence of and mortality from prostate
cancer has led to widespread calls for prostate cancer
screening. However, the subject is controversial [1-3]. PSA
testing has high false positive rates and there is the poten-
tial for over-diagnosis of slow growing prostate cancers
that may never present as a problem. Furthermore there is
no strong evidence that treatments for localised cancer are
effective, and no good evidence at present that screening
would result in a reduction of mortality. Screening could
therefore result in more harm than good [1].
Randomised trials are currently underway in Europe and
the US to assess the impact of screening [4]. Definitive
information from these trials will not be available until
later this decade. Recent falls in mortality in the US [5],
where there is widespread PSA testing, are often cited as
being indicative of successful screening. However, inter-
pretation of this data is complex, with factors such as lead-
time bias (where PSA testing has prolonged the length of
time a patient is identified as having the disease without
prolonging their life) and length bias (where PSA testing
has resulted in increased diagnosis of slow-growing or
non-progressing tumours with a good prognosis) contrib-
uting to this outcome [6].
In the UK, the National Screening Committee has recom-
mended that a prostate cancer screening programme
should not be introduced at this time [7]. However, in
response to growing public concern about prostate cancer,
in 2001 the Department of Health introduced a Prostate
Cancer Risk Management Programme (PCRMP) [8],
which provides men with access to the PSA test, provided
they have been given full information regarding its' possi-
ble benefits and limitations.
While rates of PSA testing in England and Wales have been
assessed previously [9], there is very little evidence to date
regarding general practitioners' (GPs) current practice in
testing for prostate cancer. Furthermore, while surveys
conducted in Australia, NZ and USA have reported GPs'
knowledge and opinions of PSA testing for prostate cancer
[10-14], little is known about GPs' current views towards
PSA testing in the UK. One survey conducted in 1998 with
GPs in the North Staffordshire district of England found
that 81% (134/167) GPs agreed there should not be a
population screening programme at that time [15]. How-
ever, 57% (93/163) felt that if patients are educated about
the benefits and limitations then they should be allowed
to make their own decision about being tested. Only 9%
(15/168) of GPs in this survey reported testing asympto-
matic men, although nearly two-thirds of respondents
reported that they or their staff were asked about prostate
cancer screening by their patients.
The main aims of this study were to determine GPs' cur-
rent reported practice regarding PSA testing, and to assess
their views regarding current policy on informed decision-
making and PSA testing.
Methods
A questionnaire was developed and piloted with a sample
of 30 GPs from the Oxfordshire GP research consortium
and GP contacts in Wales and Hertfordshire in September
2003. The survey was hosted by MEDIX, a web-based
internet service provider for doctors http://www.medix-
uk.com. MEDIX has a user group of 12,000 doctors, with
4,700 GPs registered from a wide demographic base and
with a wide distribution in terms of decade qualified.
Male GPs are over-represented in the database (79%). No
remuneration or incentives were offered for participating
in this survey (although GPs registered with MEDIX are
offered incentives for participating in certain types of
online research). A random sample of 421 GPs from the
MEDIX database were e-mailed an invitation to take part
in the survey. The e-mail contained a link to the question-
naire which addressed GPs' reported practice and views
using a combination of direct questions and 5 consulta-
tion vignettes. The first two vignettes described men aged
55 and 70 years respectively who presented with mild
lower urinary tract symptoms (LUTS). There was no men-
tion in the vignette that the men had raised the issue of
prostate cancer or PSA testing. The third man presented
with concerns about his family history of prostate cancer
(his father died aged 75 of prostate cancer and his brother
had been diagnosed last week) and asked to be tested for
prostate cancer. The fourth and fifth men were asympto-
matic (aged 55 and 70 years respectively), but had both
recently lost a friend to prostate cancer, and asked to be
tested for prostate cancer. The survey was posted on 24/
11/03. All responses were received within 30 hours.
Results
The participants
The response rate was 95% (400/421). Of these, 94%
(375) were partners in a GP practice, 4% (16) were GP
assistants, and 2% (9) were GP registrars. The majority
were full time (86%, 343), and male (82%, 327). There
was a wide coverage by region across the UK (for example
15% (59) from the South-East, 9% (36) from the South-
West, 10% (39) from the North West, 12% (49) from
Scotland and 5% (21) from Wales). There was also a
broad range from decade qualified, with 3% (14) quali-
fied in the 1960s, 31% (125) qualified in the 1970s, 43%
(173 qualified in the 1980s, 21% (85) qualified in the
1990s, and 1% (3) qualified in the 2000s. When com-
pared with national statistics for GPs [16], female GPs, as
expected, were significantly under-represented in this
sample (18% vs 36%), as were non-partner GPs (6% vs
15%).BMC Family Practice 2005, 6:24 http://www.biomedcentral.com/1471-2296/6/24
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General Practitioners' reported practice
Table 1 below reports the tests which GPs reported they
would elect to conduct for each of the vignettes. GPs were
significantly more likely to report they would do a PSA
test for a man who presents with concerns about his fam-
ily history and requests a test, than for men who present
with either mild lower urinary tract symptoms (LUTS) (p
< 0.0001) or asymptomatic men who request a test (p <
0.0001). GPs were also significantly more likely to report
they would do a PSA test for a 70 year old than for a 55
year old man either presenting with LUTS, or requesting a
test in the absence of symptoms. GPs also frequently
reported they would do a digital rectal examination (DRE)
either if the man requested a test because of his family his-
tory, or presented with mild lower urinary tract symp-
toms. Less than half of the GPs reported they would do a
DRE if the man was asymptomatic, but were significantly
more likely to do one for a 70 year old than a 55 year old
asymptomatic man in this situation.
When asked approximately how many asymptomatic
men they had discussed PSA testing for prostate cancer
with in the past 3 months, 12% (48) reported none, 65%
(259) reported discussions with between 1 and 5 men,
17% (68) reported discussions with between 6 and 10
men, and 6% (25) reported discussions with more than
10 men.
Twenty-four percent (94) of GPs said they had not con-
ducted any PSA tests for asymptomatic men in the past
three months, 63% (252) reported they had tested
between 1 and 5 asymptomatic men, 9% (37) reported
between 6–10 men, and 4% (17) reported more than 10
men.
Regarding the role of practice nurses in the PSA testing
process, 76% (304) said nurses were not involved, 16%
(63) said the nurse conducts PSA testing following coun-
selling from the GP, and 4% (16) reported that nurses
conduct both counselling for the test and taking the
sample.
General practitioners' views towards PSA testing
67% GPs responded that they supported the current pol-
icy. When specifically asked to indicate their preference
for a national PSA testing policy, six percent (22) GPs
believed PSA testing should not be available to asympto-
matic men and 33% (132) GPs would prefer selective
screening of high risk men. 8% (31) GPs said they would
like to see the introduction of a population screening pro-
gramme. The remainder supported patient or GP initiated
screening, or a combination of both. No associations were
found between years practising as a GP or gender of GP
and the views expressed above.
Informed decision-making
When asked how GPs would prefer men to make their
decision regarding whether or not to have the PSA test,
49% (196) said the man should make the final decision
after seriously considering his GP's opinion, 34% (135)
said the GP and the man should share the responsibility,
13% (51) said the man should make the final decision
completely by themselves, 4% (17) said the GP should
make the final decision, after seriously considering the
man's opinion, and 1% (2) said the GP should make the
final decision.
GPs also indicated how they would prefer to conduct a
consultation regarding PSA testing – 55% (219) of GPs
reported they would prefer to discuss the benefits and lim-
itations of PSA, provide the man with written informa-
tion, and request that the man makes another
appointment if they decide to be tested; 35% (140) of GPs
reported they would provide the counselling and then
Table 1: Reported use of tests by general practitioners (N = 400)
Vignette Mild lower urinary 
tract symptoms 
(55 years)





requests test (55 
yrs)
Asymptomatic, 
requests test (55 
yrs)
Asymptomatic, 
requests test (70 
yrs)
% (95% CI) n%   (95% CI) n%   (95% CI) n%   (95% CI) n%   (95% CI) n
Prostate Specific 
Antigen (PSA)
60% (55,64) 239 78% (73,82) 311 91% (87,93) 363 60% (55,65) 239 71% (66,75) 282
Digital rectal 
examination (DRE)
69% (64,73) 274 78% (73,81) 310 67% (62,72) 268 37% (32,42) 147 47% (42,52) 189
Trans-rectal 
ultrasound
2% (1,4) 97 %   (4,10) 27 10% (7,13) 41 1% (0,2) 22 %   (0,4) 7
No tests 6% (4,9) 25 3% (2,5) 13 3% (1,5) 11 22% (18,26) 88 14% (11,18) 58
Other* 47% (42,52) 188 41% (36,46) 165 14% (11,18) 56 17% (14,21) 69 13% (10,16) 51
*Other mainly includes mid-stream urine, other urinary checks and discussion / counselling.BMC Family Practice 2005, 6:24 http://www.biomedcentral.com/1471-2296/6/24
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perform the PSA test within the same consultation if the
man still wishes to be tested; 5% (20) said they would
conduct the test without counselling, but explain why
they are conducting the test, and 3% (13) would reassure
the man that he did not need a PSA test.
Discussion
This study of UK GPs indicates that PSA testing of asymp-
tomatic men is a common occurrence, and that consulta-
tions which involve a discussion of PSA testing often
result in the test being performed. Most GPs in the study
reported they would perform a PSA test for men con-
cerned about their family history of prostate cancer. Most
reported they would also test men who present with mild
LUTS, or who request a 'screening' test in the absence of
any symptoms – particularly older men. An Australian
study has also suggested that age and LUTS may provide
'cues' to action for PSA testing [16]. The distinction
between a 'screening' and 'diagnostic' PSA test tends to
become blurred as men get older and the presence of
some degree of urinary symptoms becomes increasingly
common. Even if urinary symptoms are present there is
disagreement amongst experts as to whether the PSA test
should be routine or whether men should 'opt in' to hav-
ing the test [17]. Urinary symptoms are most often caused
by benign prostatic hypertrophy (BPH), and there is a very
weak evidence base for the primary care diagnosis of pros-
tate cancer in men with LUTS [18]. Early, localised pros-
tate cancer usually does not produce symptoms and by the
time prostate cancer is causing urinary symptoms it is
likely to have reached an advanced stage, where treatment
options are reduced. Some men will have a co-existing
early prostate cancer and BPH, and when a man seeks
advice about LUTS this can set in train investigations
which diagnose a coincidental prostate cancer. Coping
with a positive PSA test performed with no prior warning
could be distressing for some men, and research is needed
to explore the level of counselling occurring in men with
LUTS prior to PSA testing in primary care.
Although the current policy recommendation in the UK is
that a DRE is not warranted in asymptomatic men [19],
almost half of the GPs in the survey indicated they would
perform a DRE for an asymptomatic 70 year old man con-
cerned about prostate cancer, and over a third for a
younger man. Previous studies have also reported
endorsement of use of both the PSA and DRE in asympto-
matic men [20,21], and it has been suggested that this
may be because the DRE is seen as a routine component
of a physical examination for men [12]. The American
Cancer Society has also recommended the use of both
[22], although the US Preventive Services Task Force con-
cludes that the evidence is insufficient to recommend for
or against routine screening for prostate cancer using PSA
or DRE [23].
In line with the reported practice of GPs, the survey found
that whilst GPs do not support the introduction of a
national PSA screening programme, there is support for
the current policy of providing men with access to the test,
provided they have been given prior information on the
benefits and limitations. Most respondents in this survey
favoured both the GP and the man sharing in the deci-
sion-making process and the largest proportion indicated
they would prefer to counsel men first and then take the
blood sample during a separate consultation. Facilitation
of informed decision-making is a key element of policy,
but there is currently little evidence about how best to
organise services to achieve an informed decision. One
study reported that conducting prenatal screening in the
same appointment, as opposed to requiring a return visit,
may lead to higher levels of informed choice [24].
Another study assessing cystic fibrosis screening found
patient choice was based on more knowledge when test-
ing was part of a separate visit [25]. Separating informa-
tion provision from PSA testing would require more
consultation time, and would be less convenient for a
man who knows he wants to be tested. Additionally, there
may be a perception that because testing was not offered
at the time the GP does not really support testing. Con-
versely, with same-day testing the patient may be more
influenced by the GP's opinions and may not have had
sufficient time to fully understand and consider the bene-
fits and limitations.
Research is needed to assess the most effective way of
achieving and measuring informed decision making for
PSA testing. In addition, attempts to study the informed
decision-making process need to take into account the dif-
ferent influencing factors. As well as knowledge and the
way testing is organised, personal attitudes and values, the
attitudes of health professionals, and social and media
influences can all affect the decision.
This study has some limitations. The sample was drawn
from a database of GPs registered with one particular
internet service provider and whilst previous studies have
demonstrated the acceptability of the internet as a
resource for medical research in primary care [26], there
are also recognised drawbacks [27]. The main limitation
of the study is the potential for selection bias. As we
expected from the profile of GPs registered with MEDIX,
in comparison with national GP statistics [28] female doc-
tors are under-represented in our study. We do not, how-
ever, believe this to be a major issue for this particular
topic as anecdotal evidence from many GPs (both male
and female) would indicate that the majority of consulta-
tions which include a discussion of prostate issues occur
with male GPs. In support of this, some recent pilot work
we have conducted found that 90% of GP responders to a
survey sent out following a request for a PSA test wereBMC Family Practice 2005, 6:24 http://www.biomedcentral.com/1471-2296/6/24
Page 5 of 6
(page number not for citation purposes)
male. The sample is, however, also likely to have over-rep-
resented internet literate GPs who may not be representa-
tive of the wider GP community. A further important
limitation of the study is the use of consultation vignettes
to seek GP's reported behaviour. The vignettes can only
provide minimal information about the patient / consul-
tation, sometimes making expected behaviour difficult to
predict. We also acknowledge the potential difference
between reported and actual behaviour with respondents
more likely to report what they perceive to be 'appropri-
ate' behaviour than what they may actually do in practice.
It is important that future studies in this area address the
actual behaviour of GPs.
Overall PSA testing rates in the UK are rising [29].
Although the exact proportion of asymptomatic men
being tested, and the extent to which this is patient driven,
is unknown, a recent study reports that the rate of asymp-
tomatic testing in general practice is at least 1.6% per
annum and higher if private testing is included [9]. With
the increasing media attention being given to prostate
issues it is expected that these rates will continue to rise
and it is therefore important there is adequate considera-
tion of the implications for both primary and secondary
care. The Prostate Cancer Risk Management Programme
has circulated an information pack on this topic to GPs
http://http:\\www.cancerscreening.nhs.uk/prostate/infor
mationpack.html, but it is likely that a multi-faceted
approach is required for the successful dissemination of
this information to primary care [30].
Conclusion
This study indicates that PSA testing in asymptomatic men
is a regular occurrence in the UK, and that there is general
support from GPs for the current policy of making PSA
tests available to 'informed' men who are concerned
about prostate cancer. While most GPs in the study indi-
cated they would discuss the benefits and limitations
prior to PSA testing, and most GPs favoured a shared
approach to decision making, it is not known to what
extent men are actually being informed. Research is
required to determine the most effective approach to
assisting men in making an informed decision about
whether or not to have a PSA test.
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